Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Thorbjørn Grøfte, Simon Lambden et al.|The Lancet Respiratory Medicine|2023Cited by 76
sTREM-1 is a specific biomarker of TREM-1 pathway activationLucie Jolly, Marc Derive, Kévin Carrasco et al.|Cellular and Molecular Immunology|2021Cited by 75
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trialBruno François, Pierre‐François Laterre, Valérie Cuvier et al.|Intensive Care Medicine|2020Cited by 71
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trialBruno François, Sébastien Gibot, Simon Lambden et al.|EClinicalMedicine|2023Cited by 18